New Training Initiative and Expanded U.S. Professional Affairs Team Further Commitment to Advance Myopia Management as Standard of Care
SAN RAMON, CALIF., April 11, 2024—CooperVision today announced two significant advancements to educate and support U.S. eye care professionals (ECPs) as they enter into and continue with myopia control in their practices. The company’s new MiSight® 1 day* QuickStart Program has been introduced to simplify the process of prescribing MiSight® 1 day contact lenses for ECPs. Additionally, CooperVision has expanded its dedicated myopia management team to provide additional professional support to combat the growing epidemic.1
The MiSight® 1 day QuickStart program, accessible via CooperVision’s Online Success Center, caters to ECPs at various stages of their prescribing journey with MiSight® 1 day, the first and only FDA-approved* soft contact lens proven to slow the progression of myopia in children, aged 8-12 at the initiation of treatment.†2
The tools include written guides, a series of short videos, and amplified support from CooperVision’s Myopia Management Specialist team members, allowing ECPs to tailor their learning experiences. The topics span from essential clinical information required for initiating treatment to effective communication strategies with parents, ensuring their entire practice is engaged in supporting patients.
“CooperVision strives to make prescribing as easy as possible for ECPs, especially with a growing number who want to take an active role in combatting the growing prevalence of myopia” said Justin Kwan, OD, FAAO, who has been promoted to Head, Myopia Management. “Our MiSight® 1 day QuickStart program accelerates this pathway. It facilitates myopia treatment for children, which has the potential to positively impact their lives and improve the trajectory of their vision health.”‡3,4
CooperVision is also expanding its U.S. professional myopia team to ensure that every practicing ECP has access to specialized expertise. Priscilla Chang, OD FAAO, IACMM, has joined CooperVision as Senior Manager, Myopia Management. Dr. Chang previously served as a Clinical Sales Consultant for Johnson & Johnson Vision. She joins Leah Johnson, OD, FAAO, FSLS, FBCLA and Felicia Timmermann, OD, MS, FAAO, Senior Managers, Myopia Management. These experienced professionals bring deep knowledge in myopia control to their support of doctors and staff, under Dr. Kwan’s leadership.
“CooperVision’s commitment to providing the eye care community with the highest quality tools, products, and services starts first by investing in our people,” said Dr. Kwan. “Through this team of Drs. Chang, Johnson and Timmermann, we’re elevating peer-to-peer interaction, practice support, and education across the country, while helping the profession establish myopia management as the standard of care.”5
###
* Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3 year period.
‡ 77% strongly agree, 20% somewhat agree.
1. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
3. Rah MJ, et al. Vision specific quality of life of pediatric contact lens wearers. Optom Vis Sci. 2010;87(8):560-6.
4. CVI data on file 2022. U.S. CooperVision online survey: ECP MiSight® 1 day Perspectives; n=101 ECPs that prescribe MiSight® 1 day
5. Resolution: The standard of care for Myopia Management by Optometrists. World Council of Optometry. (2021, May 17). https://worldcouncilofoptometry.info/resolution-the-standard-of-care-for-myopia-management-by-optometrists.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com
Media Contact
Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153